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Abstract
Background: Since genetic alterations influencing susceptibility to multiple sclerosis (MS), the
most common autoimmune demyelinating disease of the central nervous system (CNS), are as yet
poorly understood, the purpose of this study was to identify genes responsible for MS by studying
monozygotic (MZ) twin pairs discordant for MS.
Methods: In order to identify genes involved in MS development, the gene expression profiles in
blood mononuclear cells obtained from eight MZ twin pairs discordant for MS were analyzed by
cDNA microarray technology detecting the expression of 8 300 genes. The twins were collected
from the Finnish Twin Cohort Study and both affected subjects and their healthy siblings underwent
neurological evaluation and cerebral and spinal magnetic resonance imaging. Gene expressions
were confirmed by relative quantitative reverse transcription PCR.
Results: It appeared that 25 genes were at least two-fold up-regulated and 15 genes down-
regulated in 25% (2/8) of twins with MS when compared to their healthy siblings. Moreover, 6/25
genes were up-regulated in 40% of MS twins and one gene, interferon alpha-inducible protein (clone
IFI-6-16) (G1P3), in 50% of them. The six most constantly expressed genes are (1) G1P3, (2) POU
domain, class 3, transcription factor 1, (3) myxovirus resistance 2, (4) lysosomal-associated
multispanning membrane protein-5, (5) hemoglobin alpha 2 and (6) hemoglobin beta.
Conclusion: Over two-fold up-regulation of these six genes in almost half of MZ twins with MS
suggests their role in MS pathogenesis. Studies using MZ MS twins obtained from genetically
homogeneous population offer a unique opportunity to explore the genetic nature of MS.
Background
Multiple sclerosis (MS) is the most common autoimmune
demyelinating disease of the central nervous system
(CNS) characterised by inflammatory lesions scattered
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prevalence of MS in Finland is the highest in the world
being 100/100 000, although the figures vary in different
regions of the country [1]. The reasons for the increase in
the disease prevalence are not known, although viral
infections and other environmental factors have been sug-
gested [1].
Family and twin studies have shown that the concordance
rate of MS for monozygotic (MZ) twins is about 30% and
2 – 5% for dizygotic (DZ) twins and siblings [2-4]. In a
Finnish twin cohort of 15 815 pairs, the concordance rate
of MS was 29% in MZ twins and the concordance rate was
0% in DZ twins [5].
It is well known that genetic factors regulate susceptibility
to MS, but of these factors only HLA-DR2 has been con-
firmed to be associated with the disorder [6]. In our previ-
ous studies several susceptibility genes and their
associations have been reported [7-15]. These are the pro-
tective effect of HLA-DR1 and HLA-DR53 combination
against MS [9], decreased risk of severe MS of IL-10-1082
AG genotype carriers [12] and high chemokine receptor 5
(CCR5) RNA expression in peripheral blood in primary
progressive MS [8]. Increased risk of MS in women has
been detected with interleukin-1 receptor antagonist (IL-
1RA) allele 2 [11], 5G5G genotype of plasminogen activa-
tor inhibitor 1 (PAI-1) gene [10] and interaction between
estrogen receptor 1 (ESR1) and HLA-DR2 [13]. Other
associations with MS in Finnish population are myelin
basic protein (MBP) short tandem repeat [15], intercellu-
lar adhesion molecule-1 (ICAM-1) AA genotype (Lys469/
Lys469) [14] and preliminary evidence of two distinct MS
susceptibility genes, proximal rs3977 and distal
D2S1271-associated genes, on 2q33 outside of cytotoxic
T-lymphocyte-associated 4 (CTLA4) gene [7]. Taken
together, these observations suggest that experimental
approach using MZ twin pairs discordant for MS obtained
from Finnish genetically relatively homogeneous popula-
tion may provide a unique opportunity to explore the
genetic nature of MS. Interestingly, one study performed
on monozygotic twins with MS reported deficient expres-
sion of the inhibitory transcription factor Sp3 in mononu-
clear blood cells [16].
Since genetic factors influencing MS susceptibility and
progression are as yet poorly understood, the purpose of
this study was to identify genes responsible for MS devel-
opment by studying MZ twin pairs discordant for MS
identified from the Finnish Twin Cohort Study and using
cDNA array technology involving the expression profiles
of 8 300 known genes.
Methods
Study subjects
We studied eight MZ twin pairs discordant for MS
obtained from the Finnish Twin Cohort Study. Patients of
MS were identified by linkage to the national hospital dis-
charge registry, which covers all hospitalization in Finland
since 1972. All the twin pairs, both affected subjects and
their healthy twin siblings, underwent neurological evalu-
ation and magnetic resonance imaging (MRI) of the CNS
using 1,5 Tesla MRI unit during a clinical remission of the
disease. From the MRI protocol, axial 3 dimensional (3D)
T2 fast spin echo (FSE), T1 3D axial spoiled gradient echo
(SPGR) and FLAIR sequences were used. T2 hyperintense
plaques were analyzed from 3D T2 FSE images, T1
hypointense plaques from 3D T1 SPGR images and FLAIR
lesions from FLAIR images. All MS patients showed T1-
and T2-lesions characteristic to MS, but Gadolinium-
enhanced focal lesions were not detected. The diagnosis of
MS was based on Poser's criteria and all diagnoses were
definite [17]. The affected twins had no other diseases and
their twin siblings were all healthy. The mean age of twin
pairs was 51.1 ± 9.1 (SD) years. The neurological disabil-
ity evaluated by the Expanded Disability Status Scale
(EDSS) score was 5.1 ± 1.9 (mean ± SD). The clinical char-
acteristics of twin pairs are shown in Table 1. Four out of
8 twins with MS were treated with interferon beta (IFN-β).
One of them had received this treatment for 1 year
(patient No2, table 1) and the remaining three patients
for two to three years. (patients No3, 5 and 6). In addition
most of MS patients had symptomatic medication. The
peripheral blood samples were collected during a clinical
remission of the disease and the analyses were performed
blind to disease status.
Isolation of total RNA
Mononuclear cells were separated from peripheral blood
(PBMC) in VACUTAINER® CPT™ Cell Preparation Tubes
(Becton Dickinson and Company, Franklin Lakes, N.J.,
USA) and total RNA were isolated by RNeasy® Mini Kit
(QIAGEN, Valencia, CA, USA) according to the manufac-
turer's protocols. The DNA was removed according to BD
Atlas™ Plastic Microarrays (BD Biosciences Clontech, Palo
Alto, CA, USA) user manual for DNase treatment of total
RNA for 10 μg of RNA, with the exception that RNA pre-
cipitation was carried out overnight at -20°C. The quality
of total RNA was checked by gel electrophoresis and
stored at -70°C until used.
cDNA microarrays
The study was performed using BD Atlas™ Plastic Human
8 K Microarrays (BD Biosciences Clontech, Palo Alto, CA,
USA), which contains duplicate DNA fragments from
more than 8 300 known human genes (a list of genes is
available at http://www.clontech.com/clontech/atlas/
genelists/). 5 μg of total RNA were used for microarrayPage 2 of 10
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at the same time. Microarrays were exposed to phos-
phoimaging screen and scanned by StormScan 840 Phos-
phoimager (Molecular Dynamics, Sunnyvale, CA, USA)
after 5–7 days exposure time at a resolution of 50 μm to
ImageQuant software version 5.1 (Molecular Dynamics,
Sunnyvale, CA, USA). The comparison was done for all 8
discordant monozygotic twin pairs and all 8300 genes by
using widely used cDNA subtraction procedure according
to manufacturer's instructions (Clontech, Palo Alto, CA,
USA). In brief, in our array, RNA sample obtained from
healthy MZ twin (tissue No1) was compared to corre-
sponding RNA obtained from MZ twin with MS (tissue
No2) by using cDNA subtraction method.
Data analysis and normalization
Analysis was performed using the BD AtlasImage™ 2.7
Beta software (BD Biosciences Clontech, Palo Alto, CA,
USA) and data was globally normalized by the sum
method. Normalized signal intensities were compared to
those of healthy siblings. Ratios of gene expression greater
than two-fold were considered significant, based on a
99% confidence interval [18,19]. The data was further
analyzed and visualized with the GeneSpring software
version 5.0 (Silicon Genetics, San Carlos, CA, USA) and
the detailed principles of the cluster analysis and dendro-
grams can be found from the GeneSpring GX animated
tutorial from the internet http://www.chem.agilent.com/
scripts/pds.asp?lpage=27881.
Quantitative reverse transcription polymerase chain 
reaction (QRT-PCR)
The cDNA microarray data was confirmed for interferon
alpha-inducible protein gene (clone IFI-6-16) (G1P3) by
relative quantitative real-time RT-PCR with LightCycler
instrument (Roche Diagnostics GmbH, Mannheim, Ger-
many). 1 μg of total RNA was converted into cDNA with
Random Primer p(dN)6 using 1st Strand cDNA Synthesis
Kit for RT-PCR (AMV) (Roche Diagnostics Corporation,
Indianapolis, IN, USA). The primers and hybridization
probes for QRT-PCR were designed and prepared by TIB
MolBiol (Berlin, Germany) and the sequences are the fol-
lowing: forward primer: 5'-GAGTGCAGTGGCTAT-
TCACA-3', reverse primer: 5'-
GCGCATGCTTGTAATCCTAC-3', probe 5'-end labeled
with acceptor dye LC Red 640: 5'-AGCCTCAAGTGATC-
CTCCTGTCTCA-3' and probe 3'-end labeled with fluore-
cein: 5'-CATAGTACACTGCAGCCTCCAACTCC-3'.
The PCR was performed in a 20 μl total volume for target
gene with 2 μl LightCycler FastStart DNA Master Hybridi-
zation Probes (Roche Diagnostics GmbH), 3 mM MgCl2,
0.2 μM each probe, 0.5 μM each primer and 2 μl of cDNA.
The PCR was performed with a denaturation at 95°C for
10 min, amplified in 40 cycles of denaturation at 95°C for
10 s, annealing at 60°C for 15 s and elongation at 72°C
for 12 s. The cooling was performed at 40°C for 30 s.
Glucose-6-phosphate dehydrogenase (G6PDH) was used
as a reference gene. The PCR for this was performed by
LightCycler – h – G6PDH Housekeeping Gene Set Kit
(Roche Diagnostics GmbH) and was done at the same
time and under the same PCR conditions as for the target
gene. All reactions for target and reference gene were per-
formed in duplicates. Agarose gel electrophoresis was
used to verify the PCR products. QRT-PCR results were
calculated by LightCycler Relative Quantification Soft-
ware with efficiency correction (Roche Diagnostics
GmbH).
Table 1: Clinical characteristics of monozygotic twin pairs.
Twin pair no Gender Age Duration of MS (years) Type of MS EDSS Immunomodulatory treatment
1 F 54 11 SP 1.5 n.t.
F 54 Healthy/0 Healthy
2 F 48 1 RR 4.0 IFN-β-1a
F 48 Healthy/0 Healthy
3 F 55 9 SP 7.0 IFN-β-1b
F 55 Healthy/0 Healthy
4 M 53 23 SP 6.5 n.t.
M 53 Healthy/0 Healthy
5 F 33 5 RR 4.0 IFN-β-1a
F 33 Healthy/0 Healthy
6 F 54 3 RR 4.5 IFN-β-1b
F 54 Healthy/0 Healthy
7 M 66 11 SP 6.5 n.t.
M 66 Healthy/0 Healthy
8 M 46 22 SP 6.5 n.t.
M 46 Healthy/0 Healthy
F female; M male; n.t. no treatment; EDSS Expanded Disability Status Scale; IFN-β beta-interferonPage 3 of 10
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The significantly expressed genes in our array experiments
were defined according to the instructions given by the
cDNA array manufacturer (Clontech, Palo Alto, CA, USA).
cDNA subtraction ratios of gene expression greater than
two-fold were considered significant, based on a 99%
confidence interval. The differences of at least 2-fold up-
or down-regulated genes within MS twin groups were
compared with McNemar test and χ-2 test using statistical
software STATA version 8.0 (STATA Corporation, TX,
USA) A p-value of less than 0.05 was considered signifi-
cant.
Results
Gene expressions in MZ twin pairs discordant for MS
The numbers of significantly up- or down-regulated genes
(at least two-fold difference in expression between twin
pairs) in the PBMC of MZ pairs discordant for MS detected
by cDNA microarray are shown in Table 2. Comparison
between twin pairs showed that 305/8 300 genes were at
least two-fold up- or down-regulated in at least 1/8 twins
with MS. The proportion of up-regulated genes was signif-
icantly higher compared to the proportion of down-regu-
lated genes (p = 0.023 for the difference, χ-2 test).
Moreover, 38/305 genes were up- or down-regulated in at
least one fourth (2/8) of MS twin pairs (Table 2 and 3). Of
these 38 genes, 15 were down-regulated (2 to 10 fold) and
25 up-regulated (2 to 39 fold). 6/25 up-regulated genes
were expressed in at least 40% (3/8) of MS twin pairs
(Table 2), while none of the 15 down-regulated genes
were detected with this high frequency (p = 0.01 for the
difference of up- and down-regulated genes in χ-2 test).
One gene, interferon alpha-inducible protein (clone IFI-6-
16) (G1P3), appeared to be up-regulated in 50% (4/8) of
the MZ MS twin pairs.
The hierarchical relationship among ratios of gene expres-
sion of 23 most significantly expressed genes between
healthy sibling and otherwise identical sibling with MS
were compared with cluster analysis. These results are dis-
played as a dendrogram in Figure 1. As shown by the fig-
ure the twin pair samples are roughly divided into two
main branches, left branch including twin pairs 1–5 and
right branch including twin pairs 6–7. In order to find
clinical differences between the branches we characterized
these two groups according to the clinical criteria shown
in Table 1. From the left branch pairs 1–5 three had SP
type (3/5, 60%) and two RR type of MS and from the right
branch two of the twins had SP (2/3, 67%) and one RR
type of MS (Table 1). Thus these 23 genes were insufficient
to separate between relapsing-remitting and secondary
progressive MS. From the left branch pairs three (3/5,
60%) of the diseased siblings got IFN-β-1b treatment and
from the right branch pair one of the three siblings (1/3,
33%) received this treatment. Also the average EDSS,
duration of the MS and mean age of the sibling pairs
tended to be lower in the left branch subjects (mean EDSS
= 4.6, and mean duration 9.8 years, mean age 48.6 years,
respectively) than in the three subjects involved in the
right branch (mean EDSS 5.8, mean duration 12.0 years,
and mean age 55.3 years, respectively). Furthermore, four
of the total five siblings (4/5, 80%) in the left branch were
women and in the right branch two of the total tree pairs
were men (2/3, 67%).
The six most constantly expressed genes are shown in the
Table 4. They are the following: (1) G1P3, (2) POU
domain, class 3, transcription factor 1 (POU3F1), (3)
myxovirus resistance 2 (MX2), (4) lysosomal-associated
multispanning membrane protein-5 (LAPTM5), (5)
hemoglobin alpha 2 (HBA2) and (6) hemoglobin beta
(HBB). Over two-fold up-regulation of these six genes in
40% of MZ MS twins suggests their role in MS pathogen-
esis. However, no marked associations between gene
expressions and neurological or MRI findings were
detected. The expression level of G1P3 confirmed by QRT-
PCR appeared to be almost identical with the results
obtained by cDNA microarray indicating that our method
was working properly (Figure 2).
Discussion
The present study applying modern technique and exper-
imental approach where gene expression profiles of MZ
twin pairs discordant for MS were compared to each other
revealed differential expression of 305 genes out of 8300
genes studied. Among the differentially expressed genes
the proportion of up-regulated genes was significantly
higher than that of down-regulated ones (64% vs. 36%).
This observation may reflect the balance between immu-
noactivating and immunoinhibitory factors during the
complex inflammatory cascade in MS.
It is noteworthy that up-regulated expression of six genes
was found in half of twins with MS. This observation
together with the fact that the MS twins were obtained
from genetically homogeneous Finnish population sug-
Table 2: Number of up- or down-regulated genes in the 
discordant twins with MS compared to their healthy siblings.
Number of twin pairs
1/8* 2/8** 3/8
Up-regulated 194 25 6
Down-regulated 111 15 0
Total no of genes with change 305 38 6
Genes with at least two-fold change are included.
The proportion of up-regulated genes was significantly higher 
compared to the proportion of down-regulated genes within twin pair 
groups *p = 0.023; **p = 0.01 in X-2 test.Page 4 of 10
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our knowledge none of the six genes has previously been
reported to be associated with MS. The sample was rela-
tively small, but not unexpected given that MS is relatively
rare, as is MZ twinning (about 0.4% of births are MZ twin
births), The Finnish Twin Cohort covers virtually all twins
alive in 1975 and born before 1958 [20], while the hospi-
tal discharge registry identified nearly all MS cases in Fin-
land.
Expression of G1P3 was up-regulated in half of our MS
twins. It is known that this gene is transcriptionally
induced by IFN-α and -β [21-23], virus infections [24-26]
and tumour necrosis factor [27], but its function remains
unknown. It is interesting that Ifi-6-16 peptide translated
by G1P3 has been identified as an abundant self-peptide
induced following measles virus (MV) infection [28],
which has previously been associated with MS [29-31].
Since most of our MS twins were treated with IFN-β, the
Table 3: The most constantly expressed genes (n = 38) having at least two-fold change, up- (n = 25) or down- (n = 15) regulation, 
simultaneously in 2 of 8 discordant identical twins with MS when compared to their healthy siblings.
Gene group/symbol GenBank accession no. Description Up (↑) or down (↓)
– regulation of genes
Basic transcription factors
POU3F1 NM_002699 POU domain, class 3, transcription factor 1 ↑
NKX2-5 NM_004387 Cardiac-specific homeobox ↑
PHOX2A NM_005169 Aristaless (drosophila) homeobox ↑
Cell surface antigens
MX2 M30818 Myxovirus (influenza) resistance 2 ↑
LY6E NM_002346 Lymphocyte antigen 6 complex, locus E ↑
NKG7 NM_005601 Natural killer cell group 7 sequence ↓
ITGAL NM_002209 Integrin, alpha L, lymphocyte function-associated antigen 1 (CD11A) ↓
CD4 M12807 T cell surface glycoprotein CD4 antigen (p55) ↓
Growth factors, cytokines and chemokines
PPBP M54995 Pro-platelet basic protein ↓
SCGF D86586 Stem cell growth factor ↓
Intracellular transducers/effectors/modulators
VBP1 NM_003372 Von Hippel-Lindau binding protein 1 ↑
STK3 NM_006281 Serine/threonine kinase 3 (STE20 homolog, yeast) ↑ and ↓
Metabolism
HBA1 NM_000558 Hemoglobin, alpha 1 ↑
HBA2 NM_000517 Hemoglobin, alpha 2 ↑
HBB NM_000518 Hemoglobin, beta ↑
ECH1 NM_001398 Enoyl Coentzyme A hydratase 1, peroxisomal ↑
ARSA NM_000487 Arylsulfatase A ↑
HPRT1 V00530 Hypoxanthine phosphoribosyltransferase1 ↓
GAPD X01677 Glyceraldehyde-3-phosphate dehydrogenase ↓
Ribosomal proteins
RPS9 U14971 Ribosomal protein S9 ↑
RPS12 NM_001016 Ribosomal protein S12 ↑
RPS20 NM_001023 Ribosomal protein S20 ↑
RPS29 NM_001032 Ribosomal protein S29 ↑
RPL3 NM_000967 Ribosomal protein L3 ↑
RPL9 NM_000661 Ribosomal protein L9 ↑
RPL39 NM_001000 Ribosomal protein L39 ↑
LAMR1 U43901 Laminin receptor 1 ↑ and ↓
RPS5 NM_001009 Ribosomal protein S5 ↓
RPL27A NM_000990 Ribosomal protein L27a ↓
RPL30 NM_000989 Ribosomal protein L30 ↓
RPL38 NM_000999 Ribosomal protein L38 ↓
Others
G1P3 X02492 Interferon-induced protein (6–16, IFI6-16) ↑
LAPTM5 NM_006762 Lysosomal-associated multispanning membrane protein-5 ↑
AMH NM_000479 Anti-Mullerian hormone ↑
GPR6 NM_005284 G protein-coupled receptor 6 ↑
BNIP3L NM_004331 BCL2/adenovirus E1B 19 kD-interacting protein 3-like ↑
ACTB X00351 Actin, beta ↓Page 5 of 10
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explained by the IFN-β treatment or some unknown virus
infection.
Twins with MS had up-regulated expression of POU3F1.
The protein (SCIP/Oct-6) translated by this gene has
mostly been studied in the nervous system, where it is
associated with Schwann cells in the process of remyelina-
tion [32]. In oligodendrocytes, cells producing myelin in
the CNS, the SCIP/Oct-6 can stimulate the expression of
the papovaviral JC regulatory genes in progressive multi-
focal leukoencephalopathy (PML) [33], a demyelinating
disease of the CNS. However, immune response to the JC
virus has not so far been detected in MS.
Table 4: The six most constantly expressed genes detected by cDNA microarray.
Gene symbol GeneBank accession no. Description Function No of twin pairs with up-
regulated gene expression
G1P3 X02492 Interferon-induced protein 6–16 Unknown 4
POU3F1 NM_002699 POU domain, class 3, transcription 
factor 1 (SCIP/Oct-6)
Serves as transcriptional 
transactivator in the nucleus
3
MX2 M30818 Myxovirus (influenza) resistance 2 Possible antiviral potential 3
LAPTM5 NM_006762 Lysosomal-associated multispanning 
membrane protein-5
Possible involvement in B cell 
activation
3
HBA2 NM_000517 Hemoglobin, alpha 2 Oxygen transport 3
HBB NM_000518 Hemoglobin, beta Oxygen transport 3
Hierarchical clustering showing relative gene expressions comparing patients with MS to their healthy siblingsFigure 1
Hierarchical clustering showing relative gene expressions comparing patients with MS to their healthy siblings. Genes with at 
least two-fold up- or down-regulation in 25% of MS twins are presented. Housekeeping genes and ribosomal protein genes are 
not included. The colorbar on the right shows the color representation of gene expressions. Grey color indicates the lack of 
expression in cDNA microarray and twin represents twin pair. The column dendrogram on the left shows the similarity 
between the expression of different genes and column dendrogram above the similarity in the gene expression profiles of 
twins. The data was visualized with the GeneSpring software version 5.0 (Silicon Genetics, San Carlos, CA, USA) and the 
detailed principles of the cluster analysis and dendrograms can be found from the GeneSpring GX animated tutorial from the 
internet http://www.chem.agilent.com/scripts/pds.asp?lpage=27881. See also text for the interpretation of the figure.Page 6 of 10
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G1P3 gene analyzed by QRT-PCRFigure 2
G1P3 gene analyzed by QRT-PCR. Glucose-6-phosphate dehydrogenase (G6PDH) was used as a reference gene in relative 
quantification. The expression of G1P3 was on average 3.6 times higher in MS twins compared to their healthy siblings, and the 
results concurred with those obtained from cDNA microarray. Panel a shows the real-time QRT-PCR amplifications duplicate 
in each twin pair (3 – 6) and the table (panel b) shows the comparison between the cDNA microarray results and the QRT-
PCR results. The y axis indicates fluorescence intensity and x axis PCR cycle numbers. G1P3 gene amplification begins earlier in 
MS patients than in their healthy siblings, indicating higher gene expression in MS twins.
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BMC Medical Genetics 2006, 7:11 http://www.biomedcentral.com/1471-2350/7/11The MX2 gene was also up-regulated in twins with MS. Mx
proteins are induced specifically by IFN-α and -β [34,35]
and have antiviral activities [36]. The antiviral potential or
other functions of the MxB protein encoded by MX2 gene
are not fully understood, while human MxA protein has a
wide antiviral spectrum [37] and relatively high levels of
its mRNA have been detected after treatment with IFN-β
[38]. Since up-regulated MX2 gene was observed in MS
twins treated with IFN-β, its up-regulation may be
explained by this treatment or alternatively by unknown
virus infection.
The up-regulated LAPTM5 gene detected in twins with MS
is conserved across evolution but it encodes protein which
has no homology to any of the other lysosomal proteins
[39].37 LAPTM5 is also known as Clast6 and has been
found to be highly expressed in progenitor and precursor
B cells [40]. The protein may function during B cell activa-
tion or it could have a role in the antigen processing in lys-
osomes [40], which may be of relevance in MS.
Up-regulated HBA2 and HBB genes detected in MZ MS
twins translate proteins that are part of a hemoglobin
molecule. Heme units contain iron, which is involved in
myelin production by oligodendrocytes and participates
in the initiation of oxidative stress-induced injury in the
CNS [41]. It is noteworthy that this process plays a role
also in the pathogenesis of MS [41].
Conclusion
Taken together, in this study comparison of gene expres-
sion profiles in MZ MS twins to the corresponding profiles
of their healthy siblings showed over two-fold up-regula-
tion of six genes in almost half of twins with MS. This
observation is of importance taking into account the
restricted availability of MZ twins discordant for MS.
However, given the sample size, clinical variation among
subjects and limitations of the cross-sectional design, our
results should be regarded as descriptive and hypothesis
generating. To confirm the data MZ pairs discordant for
MS need to be studied in other populations. Currently we
are in a process of confirming our data with higher
number of patients with MS.
Abbreviations
CCR5 = chemokine receptor 5
CNS = central nervous system
CTLA4 = cytotoxic T-lymphocyte-associated 4 gene
DZ = dizygotic
EDSS = Expanded Disability Status Scale
ESR1 = estrogen receptor 1
G1P3 = Interferon-induced protein
HBA2 = hemoglobin alpha 2
HBB = hemoglobin beta
ICAM-1 = intercellular adhesion molecule-1
IL-1RA = interleukin-1 receptor antagonist
LAPTM5 = Lysosomal-associated multispanning mem-
brane protein-5
MBP = myelin basic protein
MRI = magnetic resonance imaging
MS = multiple sclerosis
MV = measles virus
MX2 = Myxovirus (influenza) resistance 2
MZ = monozygotic
PAI-1 = plasminogen activator inhibitor 1
POU3F1 = POU domain, class 3, transcription factor 1
QRT-PCR = quantitative reverse transcription polymerase
chain reaction
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SS carried out the experimental work and helped drafting
of the manuscript. HK carried out the neurological exam-
ination of the patients and participated in drafting of the
manuscript. RP, MK and NA participated in the experi-
mental work. TL, JK and MK helped to plan the study and
to draft the manuscript. IE was the responsible investiga-
tor of the study and participated in planning of the study
and drafting of the manuscript.
Acknowledgements
The authors thank Shaheenul Islam M.D. for performing statistical analyses 
with STATA software. Funding for this study was provided by the Academy 
of Finland (grant number 206382) and the Medical Research Fund of Tam-
pere University Hospital.Page 8 of 10
(page number not for citation purposes)
BMC Medical Genetics 2006, 7:11 http://www.biomedcentral.com/1471-2350/7/11References
1. Sumelahti ML, Tienari PJ, Wikstrom J, Palo J, Hakama M: Increasing
prevalence of multiple sclerosis in Finland.  Acta Neurol Scand
2001, 103:153-158.
2. Ebers GC, Bulman DE, Sadovnick AD, Paty DW, Warren S, Hader W,
Murray TJ, Seland TP, Duquette P, Grey T: A population-based
study of multiple sclerosis in twins.  N Engl J Med 1986,
315:1638-1642.
3. Mumford CJ, Wood NW, Kellar-Wood H, Thorpe JW, Miller DH,
Compston DA: The British Isles survey of multiple sclerosis in
twins.  Neurology 1994, 44:11-15.
4. Sadovnick AD, Armstrong H, Rice GP, Bulman D, Hashimoto L, Paty
DW, Hashimoto SA, Warren S, Hader W, Murray TJ, Seland TP, Metz
L, Bell R, Duquette P, Gray T, Nelson R, Weinshenkar B, Brunt D,
Ebers GC: A population-based study of multiple sclerosis in
twins: update.  Ann Neurol 1993, 33:281-285.
5. Kinnunen E, Juntunen J, Ketonen L, Koskimies S, Konttinen YT, Salmi
T, Koskenvuo M, Kaprio J: Genetic susceptibility to multiple
sclerosis. A co-twin study of a nationwide series.  Arch Neurol
1988, 45:1108-1111.
6. Rasmussen HB, Kelly MA, Clausen J: Additive effect of the HLA-
DR15 haplotype on susceptibility to multiple sclerosis.  Mult
Scler 2001, 7:91-93.
7. Bonetti A, Reunanen K, Finnila S, Koivisto K, Wikstrom J, Sumelahti
ML, Pirttila T, Elovaara I, Reunanen M, Saarela J, Peltonen L, Rantamaki
T, Tienari PJ: A two-stage study on multiple sclerosis suscepti-
bility and chromosome 2q33.  Genes Immun 2004, 5:142-146.
8. Jalonen TO, Pulkkinen K, Ukkonen M, Saarela M, Elovaara I: Differ-
ential intracellular expression of CCR5 and chemokines in
multiple sclerosis subtypes.  J Neurol 2002, 249:576-583.
9. Luomala M, Elovaara I, Ukkonen M, Koivula T, Lehtimaki T: The
combination of HLA-DR1 and HLA-DR53 protects against
MS.  Neurology 2001, 56:383-385.
10. Luomala M, Elovaara I, Ukkonen M, Koivula T, Lehtimaki T: Plas-
minogen activator inhibitor 1 gene and risk of MS in women.
Neurology 2000, 54:1862-1864.
11. Luomala M, Lehtimaki T, Elovaara I, Wang X, Ukkonen M, Mattila K,
Laippala P, Koivula T, Hurme M: A study of interleukin-1 cluster
genes in susceptibility to and severity of multiple sclerosis.  J
Neurol Sci 2001, 185:123-127.
12. Luomala M, Lehtimaki T, Huhtala H, Ukkonen M, Koivula T, Hurme
M, Elovaara I: Promoter polymorphism of IL-10 and severity of
multiple sclerosis.  Acta Neurol Scand 2003, 108:396-400.
13. Mattila KM, Luomala M, Lehtimaki T, Laippala P, Koivula T, Elovaara I:
Interaction between ESR1 and HLA-DR2 may contribute to
the development of MS in women.  Neurology 2001,
56:1246-1247.
14. Nejentsev S, Laaksonen M, Tienari PJ, Fernandez O, Cordell H, Ruu-
tiainen J, Wikstrom J, Pastinen T, Kuokkanen S, Hillert J, Ilonen J:
Intercellular adhesion molecule-1 K469E polymorphism:
study of association with multiple sclerosis.  Hum Immunol
2003, 64:345-349.
15. Pihlaja H, Rantamaki T, Wikstrom J, Sumelahti ML, Laaksonen M, Ilo-
nen J, Ruutiainen J, Pirttila T, Elovaara I, Reunanen M, Kuokkanen S,
Peltonen L, Koivisto K, Tienari PJ: Linkage disequilibrium
between the MBP tetranucleotide repeat and multiple scle-
rosis is restricted to a geographically defined subpopulation
in Finland.  Genes Immun 2003, 4:138-146.
16. Grekova MC, Robinson ED, Faerber MA, Katz P, McFarland HF, Rich-
ert JR: Deficient expression in multiple sclerosis of the inhibi-
tory transcription factor Sp3 in mononuclear blood cells.  Ann
Neurol 1996, 40:108-12.
17. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers
GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New
diagnostic criteria for multiple sclerosis: guidelines for
research protocols.  Ann Neurol 1983, 13:227-231.
18. Chen Y, Dougherty ER, Bittner ML: Ratio-Based Decisions and
the Quantitative Analysis of cDNA Microarray Images.  Jour-
nal of Biomedical Optics 1997, 2:364-374.
19. Claverie JM: Computational methods for the identification of
differentialand coordinated gene expression.  Hum Mol Genet
1999, 8:1821-1832.
20. Kaprio J, Koskenvuo M: Genetic and environmental factors in
complex diseases: the older Finnish Twin Cohort.  Twin
Research 2002, 5:358-365.
21. Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR: Transcrip-
tional and posttranscriptional regulation of interferon-
induced gene expression in human cells.  Cell 1984, 38:745-755.
22. Hibbert L, Foster GR: Human type I interferons differ greatly in
their effects on the proliferation of primary B cells.  J Interferon
Cytokine Res 1999, 19:309-318.
23. Kelly JM, Porter AC, Chernajovsky Y, Gilbert CS, Stark GR, Kerr IM:
Characterization of a human gene inducible by alpha- and
beta-interferons and its expression in mouse cells.  Embo J
1986, 5:1601-1606.
24. Clauss IM, Wathelet MG, Szpirer J, Content J, Islam MQ, Levan G,
Szpirer C, Huez GA: Chromosomal localization of two human
genes inducible by interferons, double-stranded RNA, and
viruses.  Cytogenet Cell Genet 1990, 53:166-168.
25. Wathelet MG, Clauss IM, Paillard FC, Huez GA: 2-Aminopurine
selectively blocks the transcriptional activation of cellular
genes by virus, double-stranded RNA and interferons in
human cells.  Eur J Biochem 1989, 184:503-509.
26. Zhu H, Zhao H, Collins CD, Eckenrode SE, Run Q, McIndoe RA,
Crawford JM, Nelson DR, She JX, Liu C: Gene expression associ-
ated with interferon alfa antiviral activity in an HCV replicon
cell line.  Hepatology 2003, 37:1180-1188.
27. Chernajovsky Y, Reid TR: Regulation of the human interferon-
inducible 6–16 promoter in tumor necrosis factor-sensitive
and resistant mouse cells: role of cAMP as a mediator of sig-
nal transduction.  J Interferon Res 1990, 10:627-636.
28. Herberts CA, van Gaans-van den Brink J, van der Heeft E, van Wijk
M, Hoekman J, Jaye A, Poelen MC, Boog CJ, Roholl PJ, Whittle H, de
Jong AP, van Els CC: Autoreactivity against induced or upregu-
lated abundant self-peptides in HLA-A*0201 following mea-
sles virus infection.  Hum Immunol 2003, 64:44-55.
29. Liebert UG, ter Meulen V: Synergistic interaction between mea-
sles virus infection and myelin basic protein peptide-specific
T cells in the induction of experimental allergic encephalo-
myelitis in Lewis rats.  J Neuroimmunol 1993, 46:217-223.
30. Link H, Sun JB, Wang Z, Xu Z, Love A, Fredrikson S, Olsson T: Virus-
reactive and autoreactive T cells are accumulated in cere-
brospinal fluid in multiple sclerosis.  J Neuroimmunol 1992,
38:63-73.
31. Ohara Y: Multiple sclerosis and measles virus.  Jpn J Infect Dis
1999, 52:198-200.
32. Sim FJ, Zhao C, Li WW, Lakatos A, Franklin RJ: Expression of the
POU-domain transcription factors SCIP/Oct-6 and Brn-2 is
associated with Schwann cell but not oligodendrocyte remy-
elination of the CNS.  Mol Cell Neurosci 2002, 20:669-682.
33. Wegner M, Drolet DW, Rosenfeld MG: Regulation of JC virus by
the POU-domain transcription factor Tst-1: implications for
progressive multifocal leukoencephalopathy.  Proc Natl Acad Sci
USA 1993, 90:4743-4747.
34. Simon A, Fah J, Haller O, Staeheli P: Interferon-regulated Mx
genes are not responsive to interleukin-1, tumor necrosis
factor, and other cytokines.  J Virol 1991, 65:968-971.
35. Staeheli P: Interferon-induced proteins and the antiviral state.
Adv Virus Res 1990, 38:147-200.
36. Haller O, Frese M, Kochs G: Mx proteins: mediators of innate
resistance to RNA viruses.  Rev Sci Tech 1998, 17:220-230.
37. Haller O, Kochs G: Interferon-induced mx proteins: dynamin-
like GTPases with antiviral activity.  Traffic 2002, 3:710-717.
38. Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, Melis
F, Giordana MT: Evaluation of bioavailability of three types of
IFNbeta in multiple sclerosis patients by a new quantitative-
competitive-PCR method for MxA quantification.  J Immunol
Methods 2001, 256:141-152.
39. Adra CN, Zhu S, Ko J-L, Guillemot J-C, Cuervo AM, Kobayashi H,
Horiuchi T, Lelias J-M, Rowley JD, Lim B: LAPTM5: A Novel Lys-
osomal-Associated Multispanning Membrane Protein Pref-
erentially Expressed in Hematopoietic Cells.  Genomics 1996,
35:328-337.
40. Seimiya M, O-Wang J, Bahar R, Kawamura K, Wang Y, Saisho H,
Tagawa M: Stage-specific expression of Clast6/E3/LAPTM5
during B cell differentiation: elevated expression in human B
lymphomas.  Int J Oncol 2003, 22:301-304.
41. Connor JR, Menzies SL: Relationship of iron to oligodendro-
cytes and myelination.  Glia 1996, 17:83-93.Page 9 of 10
(page number not for citation purposes)
BMC Medical Genetics 2006, 7:11 http://www.biomedcentral.com/1471-2350/7/11Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/7/11/prepubPage 10 of 10
(page number not for citation purposes)
